ABT-737
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
ABT-737是一种新型有效的BCL-2家族蛋白抑制剂,对BCL-X L、BCL-2和BCL-w有高亲和性,而对同源性较低的BCL-B、MCL-1及A1没有亲和性。BCL-2家族蛋白对许多肿瘤细胞中细胞的存活和过表达是至关重要的。ABT-737具有在体外和体内对抗淋巴瘤,小细胞肺癌和骨髓瘤的单药活性。最近的研究表明,ABT-737可以有效的杀死急性髓性白血病细胞、祖细胞和干细胞,而保留了完整的造血细胞。ABT-737可以扰乱BCL-2/BAX复合体,并以BAK依赖,而非BIM依赖的方式激活内在的凋亡途径。
参考文献:
Marina Konopleva, Rooha Contractor, Twee Tsao, Ismael Samudio, Peter P. Ruvolo, Shinichi Kitada, Xingming Deng, Dayong Zhai, Yue-Xi Shi, Thomas Sneed, Monique Verhaegen, Maria Soengas, Vivian R. Ruvolo, Teresa McQueen, Wendy D. Schober, Julie C. Watt, Tilahun Jiffar, Xiaoyang Ling, Frank C. Marini, David Harris, Martin Dietrich, Zeev Estrov, James McCubrey, W. Stratford May, John C. Reed, and Michael Andreeff. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006: 10; 375-388
Suzanne Trudel, A. Keith Stewart, Zhihua Li, Yanjun Shu, Sheng-Ben Liang, Young Trieu, Donna Reece, Josh Paterson, Dingyan Wang, and Xiao-Yan Wen. The Bcl-2 family protein inhibitor,ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13 (2) 621-629
- 1. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.
- 2. Anna L. Koessinger, Catherine Cloix, et al. "Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics." Cell Death Differ. 2022 Oct;29(10):2089-2104. PMID: 35473984
- 3. Hector Flores-Romero, Lisa Hohorst, et al. "BCL‐2‐family protein tBID can act as a BAX‐like effector of apoptosis." EMBO J. 2021 Dec 21;e108690. PMID: 34931711
- 4. Florian J Bock, Egor Sedov, et al. "Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death." Nat Commun. 2021 Nov 12;12(1):6572. PMID: 34772930
- 5. Kirsteen J. Campbell, Susan M. Mason, et al. "Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function." Cell Death Differ. 2021 Sep;28(9):2589-2600. PMID: 33785871
- 6. Alexander-Floyd J, Haroon S, et al. "Unexpected cell type-dependent effects of autophagy on polyglutamine aggregation revealed by natural genetic variation in C. elegans." BMC Biol. 2020;18(1):18. Published 2020 Feb 24. doi:10.1186/s12915-020-0750-5. PMID: 32093691
- 7. Lee B, Min JA, et al. "A novel mechanism of irinotecan targeting MDM2 and Bcl-xL." Biochem Biophys Res Commun. 2019 Jun 25;514(2):518-523. PMID: 31056264
- 8. Thompson PJ, Shah A, et al. "Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes." Cell Metab. 2019 Feb 14. pii: S1550-4131(19)30021-X. PMID: 30799288
- 9. Rello-Varona S, Fuentes-Guirado M, et al. "Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas." Sci Rep. 2019 Mar 7;9(1):3816. PMID: 30846724
- 10. Yochum ZA, Cades J, et al. "Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer." Oncogene. 2018 Aug 31. PMID: 30171258
- 11. Jeong HJ, Ryu KJ, et al. "Anticancer agent ABT-737 possesses anti-atopic dermatitis activity via blockade of caspase-1 in atopic dermatitis in vitro and in vivo models." Immunopharmacol Immunotoxicol. 2018 Jun 29:1-8. PMID: 29957081
- 12. Kim HY, Jeong HJ, et al. "Anti-allergic and anti-inflammatory effects of the Bcl-2 inhibitor ABT-737 on experimental allergic rhinitis models." Eur J Pharmacol. 2018 May 30;833:34-43. PMID: 29856968
- 13. Cao Y, Chen M, et al. "The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses."Cell Death Dis. 2018 May 22;9(6):604. PMID: 29789637
- 14. Giampazolias E, Zunino B, et al. "Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency." Nat Cell Biol. 2017 Sep;19(9):1116-1129. PMID: 28846096
- 15. Russo M, Milito A, et al. "CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia." Oncotarget. 2017 Jun 27;8(26):42571-42587. PMID: 28489572
- 16. Joel Riley, Giovanni Quarato, et al. "Activated BAX/BAK enable mitochondrial inner membrane permeabilisation and mtDNA release during cell death."bioRxiv. 2018 February 26.
- 17. Frevert, Marie Louise. "24 drugs as potential SKP2 Inhibitors: a novel approach to finding new antidepressants. Dissertation, LMU München: Medizinische Fakultät." d-nb.info. 2017.
- 18. Xiang XY, Kang JS, et al. "SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells." Int J Oncol. 2016 Aug;49(2):773-84. PMID: 27277143
- 19. Kris Cameron Wood,Peter Saville Winter. "Compositions and Methods for Treating Cancer with JAK2 Activity." US Patent App. 15/027,216, 2016.
- 20. Moriwaki, Kenta, et al. "The Mitochondrial Phosphatase PGAM5 Is Dispensable for Necroptosis but Promotes Inflammasome Activation in Macrophages." The Journal of Immunology (2015): 1501662. PMID: 26582950
- 21. Winter PS, et al. "RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis." Sci Signal. 2014 Dec 23. PMID: 25538080
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 813.43 |
Cas No. | 852808-04-9 |
Formula | C42H45ClN6O5S2 |
Synonyms | ABT 737, ABT737 |
Solubility | ≥40.67 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
Chemical Name | 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide |
SDF | Download SDF |
Canonical SMILES | CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验: | |
细胞系 |
小细胞肺癌(SCLC)细胞系(NCI-H889、NCI-H1963、NCI-H1417、NCI-H146、NCI-187、DMS79、NCI-1048、NCI-H82、NCI-H196、H69AR和DMS114)。 |
溶解方法 |
在DMSO中的溶解度 >10 mM。为了获得更高的浓度,可以将离心管在37°C加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20°C以下储存几个月。 |
反应条件 |
48 h;10 μM |
应用 |
ABT-737作为单药活性抑制细胞增殖的能力在11种SCLC细胞系中进行评估。在H146细胞中,用活化caspase-3的底物Ac-DEVD-AMC处理24小时,ABT-737剂量依赖地增加细胞凋亡,与其剂量依赖地减少细胞活力一致,表明ABT-737通过诱导细胞凋亡,从而抑制细胞增殖。 |
动物实验: | |
动物模型 |
淋巴瘤多发Eμ-myc转基因小鼠 |
剂量 |
75 mg/kg;尾部注射 |
应用 |
与对照组小鼠相比,ABT-737(75 mg/kg)治疗小鼠的骨髓和脾脏中所有B淋巴细胞亚群均显著减少。ABT-737治疗的Eμ- myc动物骨髓中具有显著更多的凋亡细胞(**P<0.01)。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Tahir S K, Yang X, Anderson M G, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737[J]. Cancer research, 2007, 67(3): 1176-1183. [2] Kelly P N, Grabow S, Delbridge A R D, et al. Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice[J]. Cell Death & Differentiation, 2012, 20(1): 57-63. |
ABT-737是一种BH3模拟抑制剂,作用于Bcl-xL、Bcl-2和Bcl-w,非细胞试验中EC50分别为78.7 nM、30.3 nM和197.8 nM,但对Mcl-1、Bcl-B及Bfl-1没有抑制作用。 | ||||||
靶点 | Bcl-xL | Bcl-2 | Bcl-w | |||
IC50 | 78.7 nM (EC50) | 30.3 nM (EC50) | 197.8 nM (EC50) |
质量控制和MSDS
- 批次: